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EDITORIAL COMMENT
Is It Time for a Randomized
Trial of Surgical Treatment
of Ischemic Heart Failure?*
Robert H. Jones, MD, FACC
Durham, North Carolina
Should we take seriously the concluding paragraph of the
article by Athanasuleas et al. (1), in this issue of the Journal,
calling for a randomized comparison of the surgical anterior
ventricular restoration (SAVER) operation with medical
therapy or with coronary artery bypass grafting (CABG) in
patients with postinfarction dilated cardiomyopathy? Do
their uncontrolled observational data reported from a mul-
ticenter feasibility registry of outcomes indicate this new
operation is sufficiently mature to deserve a randomized
comparison with standard medical and surgical therapy? In
any case, what is standard medical and surgical therapy for
ischemic heart failure?
The authors trace the mechanistic heritage of the
SAVER operation to early left ventricular (LV) aneurys-
mectomy that appeared to reverse heart failure by lowering
LV wall stress. These linear amputations of dyskinetic scar
commonly deformed the LV blood pool into a box-like
shape. Cooley et al. (2) and Jatene (3) introduced intracav-
itary reconstruction techniques for repairing defects left by
aneurysm resection that reduced LV cavity size while
retaining a more elliptical shape. Dor et al. (4) further
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refined these operative techniques and applied them not
only to patients with dyskinetic scar but also to those with
only akinetic myocardial segments. To emphasize the op-
erative objective of restoration of LV size and shape to
normalcy over any specific operative technique, the authors
named their investigative group RESTORE and the family
of operations performed SAVER. More recently they have
applied this technique to akinetic segments in the right
coronary artery distribution and, therefore, suggest drop-
ping anterior so that surgical ventricular restoration (SVR)
becomes both the final operative objective and name.
Operative illustrations in the Athanasuleas et al. (1)
article will reassure cardiac surgeons that adoption of the
SVR operation will pose no unusual technical challenge or
learning phase cost measured by excessive patient mortality
or morbidity. The familiar LV cross-sectional diagrams
from the experimental work of Reimer and Jennings (5)
depicting the influence of duration of ischemia on progres-
sion of the wave front of irreversible myocardial damage will
aid cardiologists in understanding the objective of the SVR
operation (Fig. 1). Aggressive early management of acute
coronary syndromes in patients often arrests the ischemic
process before it reaches the transmural stage. With later
healing of infarcted myocardium, scarring is maximal in the
subendocardial region and is interlaced with normal myo-
cardium in diminishing amounts toward the epicardial
surface. Ventricular wall or chamber imaging commonly
shows an akinetic zone that gradually blends with myocar-
dium with increasingly normal function in contrast to the
dyskinetic region with a discreet neck typical of an LV
aneurysm. At the time of cardiac operation, the epicardium
of these zones may appear normal, and palpable thinning is
often minimal in the arrested, decompressed heart. This
appearance derives from preservation of a rim of normal
myocardium covering the myocardial fibrosis and contrasts
with the leather-like appearance and thinness typical of a
LV aneurysm. Unlike the LV aneurysmectomy focused on
removal of myocardial scar on the Batista operation de-
signed to reduce LV size by indiscriminate removal of
portions of the LV wall, the SVR operation attempts to
decrease the circumference of the zone of endocardial scar
through an incision in normal epicardium. The surgical
repair using the intrinsic scar or an extrinsic patch to absorb
excess linear tension in the zone relieves wall stress on the
overlying residual viable epicardial myocardium that is
closed over the repair, and thereby reduces the tendency for
continued gradual expansion of the akinetic zone. More-
over, the purse-stringing effect of the endocardial repair
acutely decreases chamber size and restores a more elliptical
shape, thereby globally decreasing wall stress and enhancing
function in myocardial regions remote from the repair.
Progression of LV enlargement typical of ischemic heart
failure, known to be a marker of increased mortality, may be
an unalterable consequence of irreversible myocardial injury
or surgical therapies that relieve chronic myocardial isch-
emia and normalize LV size and shape and may reverse this
progression and thereby enhance survival. Revascularization
alone acutely restores contractililty to myocardium previ-
ously dysfunctional from ischemia (6) and dramatically
improves LV ejection fraction in some patients with isch-
emic cardiomyopathy (7). Moreover, improvement in ven-
tricular dysfunction after CABG translates into survival
benefit (8). Revascularization alone may be all that is needed
to arrest gradual enlargement of akinetic myocardium. If so,
the added operative time and the threat of air or particulate
embolism associated with ventriculotomy to perform SVR
would be unjustified. However, perhaps revascularization of
chronically ischemic myocardium and failing to repair pre-
existing damage from the ischemia may be analogous to
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watering a plant damaged by dryness without removing
irreversibly damaged leaves that are left to sap the strength
and structure of recovering viable tissue. Whether SVR
added to CABG improves outcome will be answered only
by a randomized comparison of these two surgical options in
patients who are reasonable SVR candidates.
The SVR operation has been done with acceptable
mortality by individual thought leaders in surgery for many
years. Replication of these early results by 11 RESTORE
group centers cooperating to produce this multicenter reg-
istry report and the observed 88% 18-month survival for
patients who underwent CABG and SVR suggest that this
surgical strategy is safe and at least equivalent to CABG
alone. Technical maneuvers needed to perform SVR are
familiar to all cardiac surgeons. Moreover, the quality of
operative results can be prospectively monitored by nonin-
vasive imaging in a trial to ensure specific operative maneu-
vers used by individual surgeons attain a common standard
of optimal ventricular size and shape reconstruction. This
new operation is sufficiently mature to justify a direct
randomized comparison of CABG with SVR and CABG
without SVR in appropriately selected patients.
Further direct observational comparison of these two
surgical approaches without randomization will not define
the value of SVR added to CABG. Encouraging widespread
use to produce more data on SVR outcomes will only
increase surgical bias that may preclude ever appropriately
testing the procedure. The SVR operation now stands at a
point of information development analogous to that of
internal mammary artery use during coronary bypass graft-
ing in 1975. This conduit had been first used for direct
coronary bypass in 1964 (9) and during the subsequent
decade was championed by individual surgeons as a superior
conduit to saphenous vein. A second decade intervened
before observational patient data gradually became suffi-
ciently convincing to support its routine use. Had the added
value of internal mammary artery use in the CABG oper-
ation been addressed in the Coronary Artery Surgery Study
(CASS), a decade of uncertainty about its proper role would
have been eliminated. The million or more patients who
underwent CABG without internal mammary artery use
during this decade paid the price for needless delay with
excess death and more repeat operations. Promising opera-
tions can be evaluated too soon or too late. The present time
is ideal for objective assessment of the value SVR adds to
CABG in patients with regional akinesia and subendocar-
dial scar.
Since SVR is not a stand-alone operation for ischemic
cardiomyopathy, it must be evaluated in the context of
standard medical and surgical therapy. In any case, what is
standard medical and surgical therapy for ischemic cardio-
myopathy? Along the broad spectrum of severity of ischemic
heart failure, specific clinical information, such as severe
angina or left main coronary artery stenosis, may clearly
indicate the need for surgical therapy in some patients.
However, a large number of patients fall into a gray zone
without clear evidence for benefit from either specific
management strategy. Evidence supporting choice between
therapies was never strong and has only been confused by
recent studies showing improved outcomes with both ther-
apies. Patients for whom equipoise of anticipated benefit
now exists between modern medical and surgical therapy
represent the broad population who are appropriate candi-
dates for a randomized trial to provide the context for
assessing the value SVR adds to CABG.
To my knowledge, no randomized trial has directly
compared long-term benefits of surgical and medical treat-
ment of patients with ischemic cardiomyopathy. In the 1969
to 1972 developmental era of surgical myocardial revascu-
larization, high mortality rates were observed in patients
with heart failure. Therefore, initial randomized trials com-
paring CABG to medical treatment conducted from 1972
to 1978 excluded most of these patients from participation.
In a subgroup of 160 CASS patients with LV ventricular
ejection fraction ,0.50, the 10-year survival was 61% in the
82 medically-treated patients and 79% in the 78 patients
who underwent CABG (p 5 0.01) (10). This survival
advantage of CABG was not related to the presence or
severity of heart failure or angina symptoms. A meta-
analysis by Yusuf et al. (11) analyzed individual patient data
from CASS, and the six other early randomized trials. Only
191 (7.2%) of the 2,649 total patients had an ejection
Figure 1. Progression of cell death versus time after left circumflex coronary occlusion. Necrosis occurs first in the subendocardial myocardium. With long
occlusions, a wavefront of cell death moves from the subendocardial zone across the wall to involve progressively more of the transmural thickness of the
ischemic zone. Typically a large zone of subepicardial myocardium in the ischemic bed is salvageable by early reperfusion. In contrast, the lateral margins
in the subendocardial region of the infarct are established as early as 40 min after occlusion ([Reprinted with permission] Fig. 6 from reference 4). AP 5
anterior papillary; PP 5 posterior papillary.
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fraction ,0.40, and only 106 (4.0%) of these patients had
heart failure symptoms. Moreover, angina was a common
symptom in the few patients with symptoms of heart failure.
Coronary artery bypass grafting improved survival among all
patients with proximal left anterior descending artery ste-
nosis, three-vessel or left main coronary artery disease. In
these patients with a survival benefit from CABG, a low
ejection fraction increased the absolute benefit but did not
change the relative benefit of CABG. A literature search of
326 published reports on results of CABG in patients with
heart failure or LV dysfunction identified three well-
designed cohort studies (12). Mortality benefit of CABG
over medical therapy was 10 and 20 lives per 100 patients at
three years in two of the three studies and 29 lives per 100
patients at five years in the third study.
The therapy then called medical treatment in all random-
ized trials and most observational comparisons with CABG
was really only a reflection of coronary artery disease (CAD)
natural history since it rarely included drugs now known to
be lifesaving, such as angiotensin-converting enzyme inhib-
itors, beta-blockers, lipid-lowering drugs and antiplatelet
agents. Refinement of operative and postoperative surgical
management also has steadily improved CABG results over
the past two decades. The paucity of modern data available
to clinicians who must make daily high risk management
decisions in patients with heart failure emphasizes the need
for a properly designed randomized comparison of these
therapies commonly used in clinical practice.
The RESTORE investigators recently have been joined
by other cardiovascular specialists in planning a multicenter
international randomized Surgical Treatment for IsChemic
Heart failure (STICH) trial. If the STICH trial is approved
for funding by the National Heart, Lung and Blood
Institute, it will test two key hypotheses of surgical thera-
peutic strategy in patients with heart failure, LV dysfunction
and CAD amenable to CABG:
1. Coronary revascularization hypothesis: Improvement in
myocardial perfusion by CABG combined with aggres-
sive medical therapy improves long-term survival com-
pared to medical therapy alone.
2. Left ventricular reconstruction hypothesis: Optimal LV
shape and size reconstruction by SVR combined with
CABG and aggressive medical therapy improve long-
term survival free of cardiac morbidity compared to
medical therapy with CABG and medical therapy
alone.
Patients with heart failure, LV ejection fraction #0.35,
and CAD amenable to CABG first will be characterized by
angina intensity or left main coronary stenosis as appropri-
ate for only surgical therapy or for randomization to either
medical or surgery therapy. All patients will be further
evaluated for appropriateness of SVR indicated by dysfunc-
tion in a single LV region. Primary end points of survival
and survival free of morbidity and secondary end points of
morbidity, quality of life and cost will be compared among
treatment groups. Registries of clinical information will be
maintained for patients who are eligible but decline trial
entry. Both randomized and registry patients will be mon-
itored at regular intervals for a minimum of 3 years. Core
laboratories for radionuclide, cardiac magnetic resonance,
echocardiography, molecular biology and pVO2 studies will
support studies to elucidate mechanisms responsible for the
effectiveness demonstrated by randomized comparison of
these therapeutic strategies.
The inclusive design of this proposed trial excludes only
patients for whom medical treatment is the only reasonable
therapeutic alternative, those with coronary anatomy best
suited for revascularization by percutaneous coronary inter-
vention and those who are heart transplant candidates.
Therefore, results of the STICH trial will be generalizable
to almost all of the large number of patients in this country
with CAD, heart failure and LV dysfunction. If medical and
surgical therapies result in equivalent survival, medical
management without intensive evaluation for CAD will be
the preferred strategy of care to be pursued in the more than
300,000 patients who first present with heart failure of
unexplained etiology each year in this country. A more
aggressive search for the 70% with CAD as the etiology can
await demonstrated failure of this strategy indicated by
development of overt ischemic symptoms. Conversely, if
surgical therapy is shown to have a survival advantage over
medical therapy in the STICH trial, early aggressive eval-
uation of CAD as a correctable etiology of new onset heart
failure would be the preferred strategy.
Perhaps CABG alone will be found to be all that is
necessary to achieve maximal surgical benefit. More exciting
is the promise that surgical restoration of single zones of LV
dysfunction to a more normal size and shape contributes
survival advantage beyond CABG. This finding would
make a new therapeutic option available to millions of
patients who now suffer from ischemic heart failure.
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